0001618835-20-000218.txt : 20200910 0001618835-20-000218.hdr.sgml : 20200910 20200910200439 ACCESSION NUMBER: 0001618835-20-000218 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200908 FILED AS OF DATE: 20200910 DATE AS OF CHANGE: 20200910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PELLETIER SAUNDRA L CENTRAL INDEX KEY: 0001251371 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36754 FILM NUMBER: 201169692 MAIL ADDRESS: STREET 1: C/O EVOFEM BIOSCIENCES, INC. STREET 2: 12400 HIGH BLUFF DRIVE, SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Evofem Biosciences, Inc. CENTRAL INDEX KEY: 0001618835 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208527075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 550-1900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE STREET 2: SUITE 600 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Neothetics, Inc. DATE OF NAME CHANGE: 20140905 4 1 wf-form4_159978266397349.xml FORM 4 X0306 4 2020-09-08 0 0001618835 Evofem Biosciences, Inc. EVFM 0001251371 PELLETIER SAUNDRA L C/O EVOFEM BIOSCIENCES, INC. 12400 HIGH BLUFF DRIVE, SUITE 600 SAN DIEGO CA 92130 1 1 0 0 Chief Executive Officer Common Stock 2020-09-08 4 S 0 122500 3.26 D 360888 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.09 to $3.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. The total amount of securities beneficially owned includes 4,303 shares of common stock the reporting person purchased in accordance with the 2019 ESPP based on 85% of the closing stock price on June 12,2020, the last trading day of the purchase period. /s/ Justin J. File, attorney-in-fact 2020-09-10